Corcept Therapeutics Incorporated Shareholder Class Action Lawsuit
February 26, 2026 — The law firm of Federman & Sherwood, a national plaintiffs’ litigation firm representing shareholders and investors in complex securities matters, announced today that it has commenced an independent investigation into potential securities law violations by Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of purchasers of the Company’s common stock during the relevant period.
Details of the Lawsuit Investigation:
Federman & Sherwood’s investigation focuses on whether Corcept and certain of its officers and directors made materially false or misleading statements, and/or failed to disclose material information to investors regarding the Company’s business operations, drug development programs, regulatory outlook, financial condition, and future prospects.
The investigation will examine whether statements issued by the Company concerning clinical trial results, regulatory approvals or expectations, sales performance of key products, revenue projections, and market opportunities were accurate and complete. It also will assess whether adverse information related to clinical outcomes, regulatory interactions, market access, or competitive pressures was properly and timely disclosed to the investing public.
In addition, the investigation will evaluate whether any corrective disclosures, earnings revisions, restatements, or reduced guidance coincided with declines in the trading price of Corcept common stock, resulting in financial losses for investors who purchased or held shares based on earlier public statements.
Background:
Corcept Therapeutics Incorporated is a biopharmaceutical company focused on the development and commercialization of treatments for serious disorders related to excessive cortisol. The Company’s common stock is publicly traded, and during the relevant period, Corcept issued various statements about its clinical programs, product performance, and business outlook. Recent developments affecting the Company’s reported results and expectations have raised questions regarding the timing, accuracy, and completeness of disclosures made to the investing public.
What This Means for Investors:
Investors who purchased or otherwise acquired Corcept Therapeutics Incorporated common stock and believe they suffered financial losses may contact Federman & Sherwood for a free and confidential consultation. The firm is evaluating potential legal claims and all available remedies on behalf of affected shareholders.
CONTACT FEDERMAN & SHERWOOD
Attorney Sara Collier is widely regarded as a leading attorney in the field of derivative shareholder litigation. She is driven by a deep commitment to ensuring that boards of directors and corporate executives of publicly traded companies answer to the shareholders they serve.
With over ten years of experience pursuing derivative cases nationwide—particularly in Delaware, the home jurisdiction for many major corporations—Ms. Collier has developed a reputation for skillfully pushing even the largest companies toward stronger transparency and accountability in their corporate governance.
Phone: (405) 235-1560
Email : sec@federmanlaw.com